BLAINTRATRACHEALSUSPENSION
Approved
Jul 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
SURVANTA (beractant) by AbbVie is surfactant activity [moa]. First approved in 1991.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SURVANTA (beractant) is an intratracheal surfactant suspension approved in 1991 for respiratory distress syndrome in neonates. It works by restoring surfactant activity in the lungs, reducing surface tension and improving gas exchange. This is a first-line, life-saving therapy for premature infants with critical respiratory failure.
LOE Approaching
Long-established neonatal standard with approaching loss of exclusivity; team likely in maintenance/defensive mode focused on customer retention and volume management.
Mechanism of Action
Surfactant Activity
Pharmacologic Class:
Surfactant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SURVANTA offers stability in a critical neonatal indication but limited growth upside due to lifecycle stage and approaching LOE. Career progression likely depends on mastering defensive brand management, customer relationships, and cost optimization in a highly regulated specialty market.
Brand ManagerField Sales Representative
Worked on SURVANTA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.